|
 With 17% YOY export growth to Brazil, the Pharmaceutical Export Promotion Council of India (Pharmexcil)’s India–Brazil healthcare meeting has signalled next growth phase.
Pharmexcil recently supported the India–Brazil Healthcare Business Gateway in New Delhi, bringing together Indian pharmaceutical manufacturers, regulatory authorities, and Brazilian healthcare leaders. Organized by Amoveri Farma during the official visit of the Brazilian delegation, the closed-door meeting focused on expanding cooperation in oncology medicines, biosimilars, complex therapies, and hospital technologies, while facilitating structured access to the Brazilian market.
The meeting included participation from Amoveri Farma leadership, ANVISA representatives, and regulatory specialists, underscoring the strategic importance of India–Brazil cooperation in healthcare innovation and access. Discussions also addressed compliance with ANVISA requirements and pathways to accelerate responsible market entry.
India's pharmaceutical exports to Brazil have shown significant growth, with the country currently ranked as the second-largest destination for Indian pharma exports by share.
Based on overall export performance (Values in USD million), in FY 2024-25, total exports reached USD 778.49 million, an 18.74% increase from USD 655.64 million in FY 2023-24.
During April -January FY26 (Current Period), exports totalled USD 740.33 million, reflecting a 17.03% growth compared to the USD 632.59 million recorded during the same period in FY25.
In terms of market share, Brazil accounts for approximately 2.88% of India's total country-wise pharmaceutical exports. The majority of exports between April '25 - January '26 are driven by formulations and biologicals, which saw the highest growth during this period.
In terms of category growth and market share percentage wise, drugs formulations & biologicals grew 35.96% with a market share of 61.10%, bulk drugs & drug intermediates grew 15.26% with a market share of 29.28%, vaccines had a negative growth of -46.19% with a market share of 5.96%, surgicals witnessed a negative growth of -1.40% with a market share of 3.16% and Ayush & herbals had a negative growth of -39.45% with a market share of 0.50%.
These figures underscore the strategic importance of Brazil, particularly for Indian MSME manufacturers specializing in complex therapies and specialty medicines.
Pharmexcil chairman Namit Joshi emphasised, “Brazil represents a significant opportunity for Indian MSME pharmaceutical manufacturers, particularly in specialty medicines, public healthcare supply, technology partnerships and regulatory collaboration. Indian companies possess the technological capability as well as the manufacturing scale required to expand high-quality medicines’ access for the Brazilian population. This meeting represents a strategic step toward deepening this pharmaceutical collaboration between India and Brazil.
Pharmexcil remains committed to supporting initiatives that foster sustainable partnerships and facilitate responsible entry into the Brazilian market.”
Amoveri Farma, CEO, Guilherme Lima highlighted, “This meeting represents a significant step toward expanding pharmaceutical collaboration and improving access to advanced treatments in Brazil through partnerships with Indian manufacturers.”
As a nodal agency, Pharmexcil's commitment to global collaboration is evident through various engagements across countries. iPHEX 2026, scheduled for September 7 to 9, 2026 is also set to serve as a global platform to showcase India's pharmaceutical capabilities, fostering innovation and international partnerships. Pharmexcil continues to enhance buyer-seller communications and simplify essential processes through digital services, ensuring efficiency and increase the ease of doing business globally.
Pharmexcil is the apex export promotion council for the drugs, pharmaceutical & healthcare industry in the global arena, established by the ministry of commerce & industry, Government of India. It plays a crucial role in promoting Indian pharmaceutical exports, supporting exporters, and advancing bilateral market access and global pharmaceutical leadership. With over 4,679+ members, Pharmexcil is mandated to help them achieve excellence in exports and facilitate overseas buyers to find suitable trade partners from the Indian pharma industry.
|